Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A The Evidence Review Group (ERG) report for this appraisal was prepared by Kleijnen Systematic Reviews Ltd:

  • Riemsma R, Al MJ, Lhachimi SK et al. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis: a Single Technology Appraisal. York: Kleijnen Systematic Reviews Ltd, 2011

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I Manufacturer/sponsor:

  • Roche Products

II Professional/specialist and patient/carer groups:

  • Arthritis Care

  • National Rheumatoid Arthritis Society

  • South Asian Health Foundation

  • British Health Professionals in Rheumatology

  • British Society for Paediatric and Adolescent Rheumatology

  • British Society for Rheumatology

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (did not provide written evidence and without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare improvement Scotland

  • Abbott

  • Pfizer/Wyeth

  • Schering-Plough

  • Swedish Orphan Biovitrum Ltd

  • Arthritis Research UK

  • Kleijnen Systematic Reviews Ltd

  • National Coordinating Centre for Health Technology Assessment

C The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on tocilizumab for the treatment of systemic juvenile idiopathic arthritis by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Jeremy Camilleri, Consultant Rheumatologist, nominated by the Welsh Government – clinical specialist

  • Dr Mark Wood, Consultant Paediatric Rheumatologist, nominated by the British Society of Paediatric and Adolescent Rheumatology – clinical specialist

  • Dr Gavin Cleary, nominated by the British Society of Paediatric and Adolescent Rheumatology – clinical specialist

  • Helen Copeland, nominated by the National Rheumatoid Arthritis Society – patient expert

  • Sarah Gebbie, nominated by the National Rheumatoid Arthritis Society – patient expert

D Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche Products

  • National Institute for Health and Care Excellence (NICE)